Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
P/S ratio for Adaptimmune Therapeutics (ADAP)
P/S ratio as of May 2024 (TTM): 5.05
According to Adaptimmune Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.04502. At the end of 2023 the company had a P/S ratio of 2.99.
P/S ratio history for Adaptimmune Therapeutics from 2016 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.99 | -66.09% |
| 2022 | 8.81 | -90.75% |
| 2021 | 95.3 | -54.81% |
| 2020 | 211 | 87.41% |
| 2019 | 112 | 1013.07% |
| 2018 | 10.1 | -38.91% |
| 2017 | 16.5 | -18.08% |
| 2016 | 20.2 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 uniQure QURE | 14.3 | 183.94% | 🇳🇱 Netherlands |
 Novavax NVAX | 0.9536 | -81.10% | 🇺🇸 USA |
 Exelixis EXEL | 3.52 | -30.22% | 🇺🇸 USA |
 Enzo Biochem ENZ | 4.16 | -17.54% | 🇺🇸 USA |